Biology subjects

Bello, S. O.

Publications and source records attributed to Bello, S. O..

3 recordsLinked to original sources

bioRxiv2023

SERODIAGNOSIS OF SALMONELLA INFECTION: USING A LOGISTIC REGRESSION MODEL.

Salmonella infection remains a major global health problem and worsened by lack of appropriate diagnostic tools to aid early detection and teatment, particularly in low-income nations. Salmonella typhi is the most common causative agent of typhoid fever and the prevalence of this illness has been on the increase specifically in areas of poor personal hygiene and sanitation. This study was carried out to further improve the diagnosis of salmonella infection, through a mathematical regression model. An analysis was performed using the logistic regression approach and the predictability of the model was done by extracting fifteen (15) typhoid observations from the obtained samples; for the model to predict their status. The model was able to accurately predict 66.7% of the observations. This study showed an increased prevalence in typhoid fever including a significant correlation between typhoid fever and other parameters. The global burden of this illness can be minimized by proper vaccination, and prompt but appropriate diagnosis and treatment.Further studies and test-meaasures also needs to be carried out to improve diagnosis and treatment regimen.

microbiology↗

bioRxiv2022

Erythromycin, Retapamulin, Pyridoxine, Folic acid, and Ivermectin dose-dependently inhibit cytopathic effect, Papain-like Protease, and MPRO of SARS-CoV-2

We previously showed that Erythromycin, Retapamulin, Pyridoxine, Folic acid and Ivermectin inhibit SARS-COV-2 induced cytopathic effect (CPE) in Vero cells. In this study and using validated quantitative neutral red assay, we show that the inhibition of CPE is concentration dependent with Inhibitory Concentration-50(IC50) of 3.27 M, 4.23 M, 9.29 M, 3.19 M and 84.31 M respectively. Furthermore, Erythromycin, Retapamulin, Pyridoxine, Folic acid and Ivermectin dose dependently inhibit SARS-CoV-2 Papain-like Protease with IC50 of 0.94 M, 0.88 M, 1.14 M, 1.07 M, 1.51 M respectively and the main protease(MPRO) with IC50 of 1.35 M, 1.25 M, 7.36 M, 1.15 M and 2.44 M respectively. The IC50 for all the drugs, except ivermectin, are at the clinically achievable plasma concentration in human, which supports a possible role for the drugs in the management of COVID-19. The lack of inhibition of CPE by Ivermectin at clinical concentrations could be part of the explanation for its lack of effectiveness in clinical trials.

pharmacology and toxicology↗

bioRxiv2022

Innovative, rapid, high throughput method for drug repurposing in a pandemic - a case study of SARS-CoV-2 and COVID-19

Several efforts to repurpose drugs for COVID-19 treatment have largely either failed to identify a suitable agent or agents identified did not translate to clinical use; either because of demonstrated lack of clinical efficacy in trials, inappropriate dose requirements and probably use of inappropriate pre-clinical laboratory surrogates of effectiveness. In this study, we used an innovative algorithm, that incorporates dissemination and implementation considerations, to identify potential drugs for COVID-19 using iterative computational and wet laboratory methods that highlight inhibition of viral induced cytopathic effect (CPE) as a laboratory surrogate of effectiveness. Erythromycin, pyridoxine, folic acid and retapamulin were found to inhibit SARS-CoV-2 induced CPE in Vero cells at concentrations that are clinically achievable. Additional studies may be required to further characterize the inhibitions of CPE and the possible mechanisms. FundingTETFund Covid-19 Special Intervention Research grant(grant number TETFund/DR&D/CE/ SI/COVID-19/UDUS/VOL 1)

pharmacology and toxicology↗